Cleveland Clinic’s Genomic Medicine Institute is looking at the use of sophisticated 3-D modeling to help discern nuanced but important structural differences between germline PTEN variants associated with and predictive of a patient’s clinical condition.
A genetic mutation found only in individuals of African descent confers higher risk of chronic kidney disease. It could also be key in reducing transplant rejection.
An epileptologist teams with our Center for Clinical Genomics for a pilot study that aims to use a biorepository to enable better prediction of patient-level outcomes of epilepsy surgery.
No large-scale Parkinson’s disease genetic studies have ever been conducted in Latino populations — until now. The leader of the LARGE-PD cohort study explains its rationale and goals.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A recent study from Cleveland Clinic shows certain genomic biomarkers appear to be as important as standard clinical factors in identifying which patients are candidates for surveillance or treatment at diagnosis.
This study of a family with Cowden Syndrome and thyroid cancer revealed the role of USF3 and potential therapeutic breakthroughs.
Gone are the days of examining specimens under the microscope to diagnose cancer and determine optimal treatment. Today, Cleveland Clinic utilizes genomic sequencing for most cancers.
Recording patients’ family medical history and including it in their medical record is important in prevention, risk reduction and early detection of disease.
As key members of the Center for Personalized Genetic Healthcare, genetic counselors translate complicated data into information patients can readily understand.
The discovery of cancer-predisposing gene mutations associated with Cowden syndrome and some apparently sporadic thyroid cancers highlights how cellular stress responses can be hijacked by cancer cells to promote their survival.